Skip to main content
. 2019 Jan 17;11(1):108. doi: 10.3390/cancers11010108

Figure 2.

Figure 2

Combination of siRNA/shRNA and other cancer immunotherapies. The inhibition of the negative immune regulator in DCs results in strong immune activation. When DCs are delivered with plasmid DNA (DNA vaccine)-encoding specific tumor antigens or DCs pulsed with specific antigens, DCs-mediated anti-tumor immunity is significantly enhanced. Moreover, the monoclonal antibodies targeting CTLA-4 and PD-1 might further enhance tumor-specific immune activation.